AstraZeneca PLC said Thursday that the Phase 3 GY004 trial for its drug Cediranib didn’t meet its primary endpoint.
The pharmaceutical company said that the trial didn’t meet the
primary endpoint in the intent-to-treat population of a statistically
significant improvement in progression-free survival with the drug.
In the trial, Cediranib was added to Lynparza in platinum-sensitive relapsed ovarian cancer.
“Despite these disappointing results, we remain committed to
expanding on the benefits already demonstrated with Lynparza for
patients with advanced ovarian cancer,” Executive Vice President of
Oncology Research and Development Jose Baselga said.
https://www.marketscreener.com/ASTRAZENECA-PLC-4000930/news/AstraZeneca-Cediranib-Phase-3-Trial-Didn-t-Meet-Endpoint-30148223/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.